A 61-Year-Old Man With Stage 4 Hepatocellular Carcinoma - Episode 8
Pierre Gholam, MD: The landscape of HCC [hepatocellular carcinoma] is really evolving at a very rapid speed, as evidence by all these improvements in care. I would not hesitate to use that term. There are all these improvements in outcomes, including the very hard outcome of overall survival but also progression-free survival. There are even some recent data related to patient-reported outcomes—slowing the decrement of quality of life, and so forth.
The way to go moving forward appears to be with combinations of the immuno-oncology drugs and TKIs [tyrosine kinase inhibitors]. In some cases, combinations of immuno-oncology drugs together as in more than 1 immuno-oncology drug in combination.
These studies are fast and furious. There are too many to list right now, but certainly this audience should be on the lookout for approvals in the first line and exciting data in second line for various combinations of therapies that will hopefully enable patients to live longer and better.
There will be more clarity about the BCLC [Barcelona Clinic Liver Cancer] stage B patients. Those are patients who don’t have metastatic disease but have a large burden of illness. These have historically been less well served by local-regional therapies as we would like. Systemic therapy has not necessarily been the mainstay based on societal guidelines. But as overall survival in those patients is demonstrated to be better and treatment be better tolerated, we will see more and more of those patients receiving therapy earlier and hopefully benefiting longer from the outcome of treatment.
Transcript edited for clarity.
Case: A 61-Year-Old Man with Stage 4 Hepatocellular Carcinoma
Treatment and Follow-Up